TY  - JOUR
T1  - γδ T cells: a sparkling star for clinical immunotherapy
AU  - Zheng, Jiamian
AU  - Jiang, Xuan
AU  - Zhao, Haotian
AU  - Wang, Wandi
AU  - Wu, Xiuli
AU  - Jin, Zhenyi
Y1  - 2022///
JO  - Exploration of Immunology
VL  - 2
IS  - 4
SP  - 540
EP  - 557
DO  - 10.37349/ei.2022.00066
UR  - https://www.explorationpub.com/Journals/ei/Article/100366
AB  - Human γδ T cells are unconventional lymphocytes that function in innate and adaptive immune responses and immunosurveillance. These cells show potent cytotoxicity against tumor cells in a major histocompatibility complex unrestricted manner and have recently gained considerable attention as a sparkling star for clinical immunotherapy. Clinical immunotherapy trials with activated γδ T cells are tolerated well. However, clinical benefits are still unsatisfactory. Therefore, anti-tumor effects need to further increase the cytotoxicity of γδ T cells via several mechanisms, including the novel nitrogen-containing bisphosphonate products, adjuvant use with a bispecific antibody and chimeric antigen receptor, co-immunotherapy with γδ T cells plus immune checkpoint inhibitors, and adoptive immunotherapy with Vδ1 T cells and T cells engineered to express a defined γδ T cell receptor. Here, this article describes the crucial role of γδ T cells in anti-tumor immunity, concludes transduction strategies and summarizes the different development of novel approaches for clinical applications and cancer immunotherapy, which may be effective in overcoming current therapeutic limitations.
ER  -